Information Provided By:
Fly News Breaks for August 17, 2017
TXMD
Aug 17, 2017 | 05:59 EDT
Deutsche Bank analyst Esther Rajavelu spoke to TherapeuticsMD after the publication of the National Institutes of Health-sponsored observational study on long-term, real world use of vaginal estrogens. Management remains confident that the observational data is sufficient to demonstrate endometrial safety for TX-004 and could be a satisfactory response to the complete response letter issued in May requesting long-term safety data, Rajavelu tells investors in a research note. The data from the cohort of 32,433 women with an intact uterus demonstrate that risks of endometrial cancer and other serious adverse events were not significantly different between women who used vaginal estrogens and those who did not, the analyst writes. She continues to model TX-004 will launch conservatively in 2019. The analyst has a Buy rating on TherapeuticsMD with a $10 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD